Large DNA is critical for applications such as plasmid development, microbial genome modification, synthesis of artficial genomes, and even reading and writing in DNA. Seiji Hirasaki, CEO of Tokyo-based OriCiro Genomics, says large DNA unlocks the potential of synthetic biology: here’s how his company is addressing the challenges facing large DNA amplification.

If insulin has been around for nearly fifty years, and production has become cheaper over time, how did we get here? And what can synthetic biology do about these circumstances?

Arnold’s work to modify the chemical pathways inside biological cells started before such “metabolic engineering” was recast by some as “synthetic biology.”